4.0 Article

Evidence of DNA damage in Alzheimer disease: phosphorylation of histone H2AX in astrocytes

Journal

AGE
Volume 30, Issue 4, Pages 209-215

Publisher

SPRINGER
DOI: 10.1007/s11357-008-9050-7

Keywords

Alzheimer disease; Astrocytes; DNA damage; Neurodegeneration

Funding

  1. National Institutes of Health
  2. Alzheimer's Association
  3. Philip Morris USA Inc.
  4. Philip Morris International

Ask authors/readers for more resources

Phosphorylation of the histone family is not only a response to cell signaling stimuli, but also an important indicator of DNA damage preceding apoptotic changes. While astrocytic degeneration, including DNA damage, has been reported in Alzheimer disease ( AD), its pathogenetic significance is somewhat unclear. In an effort to clarify this, we investigated the expression of gamma H2AX as evidence of DNA damage in astrocytes to elucidate the role of these cells in the pathogenesis of AD. In response to the formation of double-stranded breaks in chromosomal DNA, serine 139 on H2AX, a 14-kDa protein that is a member of the H2A histone family and part of the nucleosome structure, becomes rapidly phosphorylated to generate gamma H2AX. Using immunocytochemical techniques, we found significantly increased levels of gamma H2AX in astrocytes in regions know to be vulnerable in AD, i.e., the hippocampal regions and cerebral cortex. These results suggest that astrocytes contain DNA damage, possibly resulting in functional disability, which in turn reduces their support for neurons. These findings further define the role of astrocyte dysfunction in the progression of AD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Clinical Neurology

MRI Monitoring of Anti-Alzheimer Therapy Amyloid-Related Imaging Abnormalities: Due Diligence or Overkill?

P. F. Hoilund-Carlsen, A. Alavi, G. Perry, J. R. Barrio

AMERICAN JOURNAL OF NEURORADIOLOGY (2023)

Editorial Material Neurosciences

Alzheimer's Disease: Not Just for the Aged?

George Perry

JOURNAL OF ALZHEIMERS DISEASE (2023)

Biographical-Item Neurosciences

Beyond the Clouds: BR Brinkley (1936-2020) Obituary

George Perry

JOURNAL OF ALZHEIMERS DISEASE (2023)

Article Plant Sciences

The International Natural Product Sciences Taskforce (INPST) and the power of Twitter networking exemplified through #INPST hashtag analysis

Rajeev K. Singla, Ronita De, Thomas Efferth, Bruno Mezzetti, Md Sahab Uddin, Sanusi, Fidele Ntie-Kang, Dongdong Wang, Fabien Schultz, Kiran R. Kharat, Hari Prasad Devkota, Maurizio Battino, Daniel Sur, Ronan Lordan, Sourav S. Patnaik, Christos Tsagkaris, Chandragiri Siva Sai, Surya Kant Tripathi, Mihnea-Alexandru Gaman, Mosa E. O. Ahmed, Elena Gonzalez-Burgos, Smith B. Babiaka, Shravan Kumar Paswan, Joy Ifunanya Odimegwu, Faizan Akram, Jesus Simal-Gandara, Magali S. Urquiza, Aleksei Tikhonov, Himel Mondal, Shailja Singla, Sara Di Lonardo, Eoghan J. Mulholland, Merisa Cenanovic, Abdulkadir Yusif Maigoro, Francesca Giampieri, Soojin Lee, Nikolay T. Tzvetkov, Anna Maria Louka, Pritt Verma, Hitesh Chopra, Scarlett Perez Olea, Johra Khan, Jose M. Alvarez Suarez, Xiaonan Zheng, Michal Tomczyk, Manoj Kumar Sabnani, Christhian Delfino Villanueva Medina, Garba M. Khalid, Hemanth Kumar Boyina, Milen Georgiev, Claudiu T. Supuran, Eduardo Sobarzo-Sanchez, Tai-Ping Fan, Valeria Pittala, Antoni Sureda, Nady Braidy, Gian Luigi Russo, Rosa Anna Vacca, Maciej Banach, Gerard Lizard, Amira Zarrouk, Sonia Hammami, Ilkay Erdogan Orhan, Bharat B. Aggarwal, George Perry, Mark J. S. Miller, Michael Heinrich, Anupam Bishayee, Anake Kijjoa, Nicolas Arkells, David Bredt, Michael Wink, Bernd L. Fiebich, Gangarapu Kiran, Andy Wai Kan Yeung, Girish Kumar Gupta, Antonello Santini, Massimo Lucarini, Alessandra Durazzo, Amr El-Demerdash, Albena T. Dinkova-Kostova, Alejandro Cifuentes, Eliana B. Souto, Muhammad Asim Masoom Zubair, Pravin Badhe, Javier Echeverria, Jaroslaw Olav Horbanczuk, Olaf K. Horbanczuk, Helen Sheridan, Sadeeq Muhammad Sheshe, Anna Maria Witkowska, Ibrahim M. Abu-Reidah, Muhammad Riaz, Hammad Ullah, Akolade R. Oladipupo, Victor Lopez, Neeraj Kumar Sethiya, Bhupal Govinda Shrestha, Palaniyandi Ravanan, Subash Chandra Gupta, Qushmua E. Alzahrani, Preethidan Dama Sreedhar, Jianbo Xiao, Mohammad Amin Moosavi, Parasuraman Aiya Subramani, Amit Kumar Singh, Ananda Kumar Chettupalli, Jayanta Kumar Patra, Gopal Singh, Tomasz M. Karpinski, Fuad Al-Rimawi, Rambod Abiri, Atallah F. Ahmed, Davide Barreca, Sharad Vats, Said Amrani, Carmela Fimognari, Andrei Mocan, Lucian Hritcu, Prabhakar Semwal, Md Shiblur Rahaman, Mila Emerald, Akinleye Stephen Akinrinde, Abhilasha Singh, Ashima Joshi, Tanuj Joshi, Shafaat Yar Khan, Gareeballah Osman Adam Balla, Aiping Lu, Sandeep Ramchandra Pai, Imen Ghzaiel, Niyazi Acar, Nour Eddine Es-Safi, Gokhan Zengin, Azazahemad A. Kureshi, Arvind Kumar Sharma, Bikash Baral, Neeraj Rani, Philippe Jeandet, Monica Gulati, Bhupinder Kapoor, Yugal Kishore Mohanta, Zahra Emam-Djomeh, Raphael Onuku, Jennifer R. Depew, Omar M. Atrooz, Bey Hing Goh, Jose Carlos Andrade, Bikramjit Konwar, V. J. Shine, Joao Miguel Lousa Dias Ferreira, Jamil Ahmad, Vivek K. Chaturvedi, Krystyna Skalicka-Wozniak, Rohit Sharma, Rupesh K. Gautam, Sebastian Granica, Salvatore Parisi, Rishabh Kumar, Atanas G. Atanasov, Bairong Shen

Summary: The development of digital technologies and open innovation approaches has enabled the creation of virtual organizations and enterprises. The International Natural Product Sciences Taskforce (INPST) is an open innovation platform that brings together individuals and organizations interested in natural product scientific research. This study presents an overview of INPST activities and showcases the use of Twitter as a powerful networking tool, demonstrated through the 2021 INPST Twitter Networking Event.

PHYTOMEDICINE (2023)

Article Multidisciplinary Sciences

Synthesize heterogeneous biological knowledge via representation learning for Alzheimer's disease drug repurposing

Kang-Li Hsieh, German Plascencia-Villa, Ko-Hon Lin, George Perry, Xiaoqian Jiang, Yejin Kim

Summary: To overcome the challenges in Alzheimer's disease drug development, researchers developed a multi-task deep learning pipeline that learns biological interactions and AD risk genes to identify repurposable drug candidates based on multi-level evidence. Mechanistic validation in neuronal cells confirmed several biologically efficacious drug combinations for reducing oxidative stress and maintaining neuronal viability and morphology. This pipeline highlights the importance of harmonizing heterogeneous and complementary data/knowledge for drug development of complex diseases.

ISCIENCE (2023)

Review Clinical Neurology

Establishment of a consensus protocol to explore the brain pathobiome in patients with mild cognitive impairment and Alzheimer's disease Research outline and call for collaboration

Richard Lathe, Nikki M. Schultek, Brian J. Balin, Garth D. Ehrlich, Lavinia Alberi Auber, George Perry, Edward B. Breitschwerdt, David B. Corry, Richard L. Doty, Robert A. Rissman, Peter L. Nara, Ruth Itzhaki, William A. Eimer, Rudolph E. Tanzi

Summary: Microbial infections can cause dementia, and their role in Alzheimer's disease (AD) pathology has long been debated. The lack of standardized detection methods has resulted in inconsistent identification of microbes in AD brains. The Alzheimer's Pathobiome Initiative aims to compare microbes in various samples to establish a consensus methodology for detection. If successful, this could lead to tailored antimicrobial treatments for patients with mild cognitive impairment or AD, potentially improving clinical outcomes.

ALZHEIMERS & DEMENTIA (2023)

Review Ophthalmology

The retina-brain axis and diabetic retinopathy

Moein Ebrahimi, Paul Thompson, Andreas K. Lauer, Sobha Sivaprasad, George Perry

Summary: Diabetic retinopathy is a major cause of vision loss and blindness, and while the changes in the retina have been extensively studied, the impact of diabetes on the rest of the visual system has been less explored. Simultaneous investigation of the retina and the brain may shed light on the neurodegenerative mechanisms in diabetics, as well as the shared mechanisms between diabetic retinopathy and other neurodegenerative disorders like Alzheimer's and Parkinson's disease.

EUROPEAN JOURNAL OF OPHTHALMOLOGY (2023)

Editorial Material Neurosciences

Playing Russian Roulette with Alzheimer's Disease Patients: Do the Cognitive Benefits of Lecanemab Outweigh the Risk of Edema, Stroke and Encephalitis?

Craig S. Atwood, George Perry

Summary: The approval of aducanumab and lecanemab by the FDA has sparked debate over their safety and efficacy. This article discusses the important physiological functions of amyloid-beta as a barrier protein, including its sealant and anti-pathogenic activities that help maintain vascular integrity and prevent encephalitis and meningitis. Approving drugs that undermine these functions may increase the risk of hemorrhage, edema, and other negative outcomes, which should be clearly communicated to patients.

JOURNAL OF ALZHEIMERS DISEASE (2023)

Article Multidisciplinary Sciences

Circulating long non-coding RNAs as novel diagnostic biomarkers for Alzheimer's disease (AD): A systematic review and meta-analysis

Parnian Shobeiri, Sanam Alilou, Mehran Jaberinezhad, Farshad Zare, Nastaran Karimi, Saba Maleki, Antonio L. Teixeira, George Perry, Nima Rezaei

Summary: This systematic review evaluated the accuracy of long non-coding RNAs (lncRNAs) in identifying Alzheimer's disease (AD) through meta-analysis. The results showed that lncRNAs had high accuracy in identifying AD and could be considered a promising diagnostic biomarker for the disease.

PLOS ONE (2023)

Article Neurosciences

Damaged mitochondria coincide with presynaptic vesicle loss and abnormalities in alzheimer's disease brain

Wenzhang Wang, Fanpeng Zhao, Yubing Lu, Sandra L. Siedlak, Hisashi Fujioka, Hao Feng, George Perry, Xiongwei Zhu

Summary: Loss of synapses is the most significant pathological feature of Alzheimer's disease (AD) that leads to cognitive deficits. This study examined synaptic deficits in AD patients and found that mitochondrial dysfunction in both pre- and post-synaptic compartments contribute to synaptic deficits in AD. These findings provide further evidence of the importance of mitochondrial dysfunction in AD pathology.

ACTA NEUROPATHOLOGICA COMMUNICATIONS (2023)

Article Information Science & Library Science

Universal research index: An inclusive metric to quantify scientific research output

Mahsa Keshavarz-Fathi, Niloufar Yazdanpanah, Sajad Kolahchi, Heliya Ziaei, Gary L. Darmstadt, Tommaso Dorigo, Filip Dochy, Lisa Levin, Visith Thongboonkerd, Shuji Ogino, Wei-Hsin Chen, Matjaz Perc, Mark S. Tremblay, Bolajoko O. Olusanya, Idupulapati M. Rao, Nikos Hatziargyriou, Maziar Moradi-Lakeh, Federico Bella, Laszlo Rosivall, Amir H. Gandomi, Armin Sorooshian, Manoj Gupta, Ciprian Gal, Andres M. Lozano, Connie Weaver, Michael Tanzer, Alessandro Poggi, Sadaf G. Sepanlou, Ralf Weiskirchen, Anet Rezek Jambrak, Pedro J. Torres, Esra Capanoglu, Francisco J. Barba, Chua Kian Jon Ernest, Mariano Sigman, Stefano Pluchino, Gevork B. Gharehpetian, Seyed-Mohammad Fereshtehnejad, Muh-Hwa Yang, Sabu Thomas, Wenju Cai, Elisabetta Comini, Neil J. Scolding, Paul S. Myles, Juan J. Nieto, George Perry, Constantine Sedikides, Nima Rezaeia

Summary: Scientometrics and bibliometrics are subfields of library and information science that study the quantity and quality of research outputs. The h-index is the most well-known scientometric index, but it relies on the count of highly cited publications. To address this limitation, we developed a new index called the Universal Research Index (UR-Index) that considers the impact of every single publication. We incorporated additional variables such as publication type, leading role, co-author count, and source metrics into the UR-Index. However, we recognize that unconscious biases in these variables may disadvantage research from specific groups, and encourage efforts to improve equitable scholarly impact in science and academia.

JOURNAL OF ACADEMIC LIBRARIANSHIP (2023)

Article Clinical Neurology

The amyloid-β pathway in Alzheimer's disease: a plain language summary

Harald Hampel, Yan Hu, John Hardy, Kaj Blennow, Christopher Chen, George Perry, Seung Hyun Kim, Victor L. Villemagne, Paul Aisen, Michele Vendruscolo, Takeshi Iwatsubo, Colin L. Masters, Min Cho, Lars Lannfelt, Jeffrey L. Cummings, Andrea Vergallo

Summary: This summary reviews the evidence supporting the role of the amyloid-b (Ab) pathway in Alzheimer's disease (AD) and emphasizes the importance of targeting this pathway in early stages of the disease. Understanding and targeting the A beta pathway can lead to better therapeutic outcomes and management of AD.

NEURODEGENERATIVE DISEASE MANAGEMENT (2023)

Book Review Neurosciences

Unaging: The Four Factors that Impact How You Age

George Perry

JOURNAL OF ALZHEIMERS DISEASE (2023)

Review Biochemistry & Molecular Biology

Roles of Oxidative Stress in Synaptic Dysfunction and Neuronal Cell Death in Alzheimer ' s Disease

German Plascencia-Villa, George Perry

Summary: Alzheimer's disease is a progressive brain disorder characterized by memory and thinking impairment, with various pathological features such as abnormal protein aggregates, synaptic dysfunction, and oxidative stress. Oxidative stress, often overlooked or considered a consequence of dementia, plays a crucial role in AD progression and neuronal death. Recognizing oxidative stress as a key factor in AD has led to the development of alternative therapeutic interventions and preventive strategies for this devastating neurodegenerative disease.

ANTIOXIDANTS (2023)

Article Medicine, General & Internal

FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimer's Disease: Benefits and Pitfalls

Poul F. Hoilund-Carlsen, Mona-Elisabeth Revheim, Tommaso Costa, Kasper P. Kepp, Rudolph J. Castellani, George Perry, Abass Alavi, Jorge R. Barrio

Summary: In June 2021, the FDA accelerated approved aducanumab and in January 2023 also lecanemab, based on perceived drug-induced removal of cerebral amyloid-beta as assessed by amyloid-PET and, in the case of lecanemab, limited clinical efficacy assumption. Approval for donanemab is pending further data. However, published trial data indicate minimal and uncertain clinical benefits, similar to conventional medication. Additionally, amyloid-PET signal decrease may reflect increased cell damage instead of amyloid removal, as supported by increased amyloid-related imaging abnormalities and brain volume loss in treated patients compared to placebo. We also question the current AD diagnostic criteria based on amyloid-PET imaging biomarkers and recommend future anti-AD therapy trials to incorporate (1) diagnosis based on cognitive decline and decreased cerebral metabolism assessed by FDA-approved FDG-PET, (2) therapy efficacy determined by cognitive ability, cerebral metabolism by FDG-PET, and brain volumes by MRI, and (3) neuropathologic examination of all deaths occurring in these trials.

DIAGNOSTICS (2023)

No Data Available